학술논문

Molecular Imaging for Estrogen Receptor-Positive Breast Cancer Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography
Document Type
article
Source
Surgical Oncology Clinics of North America. 31(4)
Subject
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Estrogen
Breast Cancer
Biomedical Imaging
Cancer
4.2 Evaluation of markers and technologies
4.1 Discovery and preclinical testing of markers and technologies
Detection
screening and diagnosis
Breast Neoplasms
Estradiol
Female
Humans
Molecular Imaging
Positron-Emission Tomography
Radiopharmaceuticals
Receptors
Estrogen
Fluoroestradiol
Molecular imaging
Breast cancer
Lobular breast cancer
Staging
Positron emission tomography
Oncology & Carcinogenesis
Oncology and carcinogenesis
Language
Abstract
18F-fluoroestradiol (18F-FES) is a Food and Drug Administration-approved radiopharmaceutical used for molecular imaging of the estrogen receptor (ER). When combined with PET, 18F-FES may improve the diagnosis of ER-positive breast cancer in the metastatic setting and provide insights into tumor heterogeneity. In this article, we review data on the use of 18F-FES imaging for treatment selection, staging, imaging lobular breast cancer, and the novel breast specific imaging tool, dedicated breast PET.